Methohexital

Methohexital: Overview

Methohexital is an ultra-short-acting methylbarbiturate derivative that functions as a potent central nervous system depressant. It is primarily utilized in clinical environments to induce general anesthesia, provide deep sedation, and facilitate brief surgical or diagnostic procedures.

What Is Methohexital & How Does It Work?

Methohexital acts as a rapid-onset, ultra-short-acting anesthetic by enhancing inhibitory neurotransmission within the central nervous system. At the cellular level, Methohexital binds to a distinct allosteric site on the gamma-aminobutyric acid subunit alpha-1 (GABA-A) receptor complex associated with a chloride ion channel. This binding prolongs the duration of time the chloride channel stays open in response to endogenous GABA. The resulting influx of chloride ions hyperpolarizes postsynaptic neurons, particularly in the thalamus and brainstem reticular activating system, suppressing neuronal firing to rapidly induce unconsciousness and deep sedation.

Is Methohexital FDA Approved?

Methohexital received official prescription approval from the United States Food and Drug Administration in June 1960 under the brand name Brevital Sodium. In a General Medicine, surgical, and emergency department setting, anesthesiologists and specialized clinicians administer Methohexital to ensure rapid, controlled anesthetic induction and procedural deep sedation.

What Is Methohexital Used For?

• Induction of general anesthesia prior to administration of maintenance anesthetic agents.
• Provision of deep sedation for short surgical, diagnostic, or dental procedures.
• Adjunctive hypnotic agent for inducing anesthesia in electroconvulsive therapy (ECT).

Before Taking Methohexital: Contraindications & Precautions

Because Methohexital induces rapid unconsciousness and respiratory depression, thorough pre-anesthetic screening is mandatory in all clinical settings.

Who Should Not Take Methohexital?

Methohexital is strictly contraindicated in patients with acute intermittent porphyria or a family history of porphyria, as barbiturates induce dangerous liver enzyme changes that trigger porphyric crises. It must not be administered to individuals with known hypersensitivity to Methantheline, Methohexital sodium, or other barbiturates. Patients lacking a secure intravenous line or those in environments without immediate resuscitation equipment must not receive Methohexital.

Methohexital: Pregnancy & Fertility

Methohexital crosses the placental barrier rapidly and can cause central nervous system and respiratory depression in the fetus or neonate. It should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the fetus. Small amounts pass into breast milk, requiring nursing mothers to pause breastfeeding for at least 24 hours following administration. Studies assessing the direct impact of Methohexital on human fertility demonstrate no conclusive evidence of permanent reproductive impairment.

Tell Your Doctor Before Taking Methohexital

Inform your anesthesiologist if you have a history of severe cardiovascular disease, heart failure, or uncontrolled high blood pressure. Disclose any existing severe liver disease, kidney dysfunction, or chronic respiratory conditions like asthma or sleep apnea. List all current prescription medications, sedatives, chronic pain drugs, and alcohol intake habits.

Methohexital: Dosage & Administration

Methohexital is administered exclusively by trained medical professionals via intravenous, intramuscular, or rectal routes in fully equipped clinical facilities.

• Intravenous Solution (1%): Administered as a rapid bolus injection for induction of general anesthesia.
• Intramuscular / Rectal Formulations: Utilized primarily in pediatric populations for non-invasive procedural sedation.
• Clinical Requirement: Must be administered only where continuous airway support and oxygenation equipment are immediately available.

Standard Methohexital Dosing

For adult induction of general anesthesia, the standard intravenous dose of Methohexital ranges from 1 mg/kg to 1.5 mg/kg administered as a slow bolus injection over 5 to 10 seconds. Anesthetic onset occurs within 30 seconds and lasts approximately 5 to 10 minutes. For maintenance of anesthesia, intermittent intravenous injections of 10 mg to 20 mg may be administered every 4 to 7 minutes, or a continuous 0.2% intravenous infusion titrated to clinical depth.

How Methohexital Is Administered

Methohexital powder for solution is reconstituted using sterile water for injection, normal saline, or 5% dextrose solution. Reconstituted solutions are visually inspected for clarity and injected directly into a running intravenous line by an anesthesiologist.

Methohexital: Clinical Efficacy & Research

Established clinical consensus confirms that Methohexital is an exceptionally effective ultra-short-acting intravenous induction agent. Clinical trials demonstrate that Methohexital provides a faster onset of action and quicker cognitive recovery compared to thiopental due to its lower lipid solubility and rapid hepatic clearance. Research confirms its unique utility in electroconvulsive therapy, where its lower seizure-threshold suppression allows effective therapeutic seizure activity while maintaining smooth, short-duration anesthesia.

Methohexital: Side Effects & Safety Profile

Methohexital possesses a narrow therapeutic safety margin, requiring continuous monitoring of respiratory and cardiovascular parameters.

Common Methohexital Side Effects

• Hiccups, coughing, and transient muscle twitching (myoclonus)
• Mild, transient blood pressure drops (hypotension) and rapid heart rate (tachycardia)
• Localized intravenous burning, vein irritation, or thrombophlebitis
• Post-procedure drowsiness, mild headache, or light confusion

Serious Methohexital Adverse Events

• Severe respiratory depression, laryngospasm, bronchospasm, and respiratory arrest
• Profound hypotension, circulatory collapse, and cardiac arrhythmias
• Severe intra-arterial injection injury, leading to arterial spasm, severe pain, and gangrene
• Acute porphyric crisis in susceptible individuals, characterized by severe abdominal pain and neurological damage

Managing Methapexital Side Effects

If respiratory depression or laryngospasm develops during administration, immediate manual bag-valve-mask ventilation, oxygenation, or endotracheal intubation must be initiated. In cases of intravenous extravasation or accidental intra-arterial injection, infusion must stop immediately, and local vasodilators or nerve blocks should be administered.

Methohexital: Interactions & What to Avoid

Combining Methohexital with other central nervous system depressants amplifies sedative and respiratory risks.

Methohexital: Interactions

• Central nervous system depressants (alcohol, opioids, benzodiazepines): Co-administration markedly potentiates severe sedation, hypotension, and life-threatening respiratory depression.
• Cytochrome P450 substrates (warfarin, oral contraceptives, phenytoin): Methohexital induces hepatic enzymes, potentially accelerating the breakdown and decreasing efficacy of these medications.
• Antihypertensive drugs: Combined use enhances vasodilatory effects, increasing the risk of sudden hypotension.

Methohexital: Food & Alcohol

Patients undergoing procedural sedation or general anesthesia with Methohexital must follow strict pre-operative fasting guidelines (nothing by mouth) to prevent aspiration. Alcohol consumption must be completely avoided before and after administration, as alcohol severely worsens respiratory depression and cognitive recovery.

Methohexital: Missed Dose, Overdose & Storage

Because Methohexital is administered on-demand by anesthesia professionals during controlled procedures, routine home dosing rules do not apply.

Missed Dose of Methohexital

Missed dose scenarios do not occur, as Methohexital is administered as a single procedure-specific dose by clinical staff in a hospital setting.

Methohexital: Overdose & Emergency

Methohexital overdose causes profound central nervous system depression, marked by deep coma, severe hypotension, hypothermia, and total respiratory arrest. Emergency treatment requires immediate airway management, mechanical ventilation, intravenous fluid resuscitation, and vasopressor support.

How To Store Methohexital

Store unreconstituted Methohexital powder vials at controlled room temperature between 20°C and 25°C (68°F and 77°F). Reconstituted solutions should be used immediately or stored for no longer than 24 hours under sterile conditions.

Methohexital: Patient Management & Monitoring

Continuous electrophysiological and vital sign monitoring is mandatory during and immediately following Methohexital administration.

Tests Before Starting Methohexital

• Pre-anesthetic physical assessment, including airway evaluation and baseline oxygen saturation.
• Baseline cardiovascular screening, including resting heart rate, blood pressure, and liver function testing.

Monitoring During Methohexital Treatment

• Continuous monitoring of pulse oximetry, electrocardiogram (ECG), end-tidal carbon dioxide, and blood pressure.
• Continuous visual observation of respiratory rate, airway patency, and depth of sedation until full recovery.

Methohexital: Do’s and Don’ts

• Do ensure advanced airway equipment and suction are fully prepared before injecting Methohexital.
• Do arrange for a responsible adult companion to escort you home after receiving procedural sedation.
• Don’t attempt to drive, operate machinery, or make legally binding decisions for 24 hours after receiving Methohexital.
• Don’t consume alcohol or taking sedatives during the recovery period following anesthesia.

Frequently Asked Questions

References

• United States Food and Drug Administration. Brevital Sodium (Methohexital Sodium for Injection) Prescribing Information.
• DrugBank Online Database. Methohexital Compound Summary (Accession Number DB00474).
• World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: N01AF01 (Methohexital).

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.